Image-defined risk factors in localized thoracic neuroblastoma and ganglioneuroma.
IDRF
INRGS
neuroblastoma
surgery
thoracic
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
13
07
2023
received:
31
03
2023
accepted:
18
07
2023
medline:
24
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
The pretreatment International Neuroblastoma Risk Group Staging System (INRGSS) discriminates localized tumors L1/L2 depending on the absence/presence of image-defined risk factors (IDRFs) at diagnosis. Referring to this new staging system, we assessed initial imaging of localized thoracic neuroblastoma (NB) and ganglioneuroma (GN) and the extent of initial tumor resection. Patients with localized thoracic NB/GN from the German clinical trials NB97 and NB2004 were included. Imaging at diagnosis and operative reports were reviewed retrospectively. IDRFs were assessed centrally and correlated to International Neuroblastoma Staging System (INSS) stage and extent of tumor resection. Additionally, we analyzed data on surgery-related complications. Imaging series of 88 patients were available for central review. In 18 children, no IDRF was present, 28 exhibited one IDRF, 42 two or more IDRFs, resulting in 70 patients with L2 disease. The most frequently observed IDRF was encasement of any vessel (n = 38). Initial surgical resection was aimed for in 45 patients (L1: n = 11; L2: n = 34). Complete and gross total resection rates were higher children with L2 NB (n = 8/25 L1, n = 17/25 L2 vs. n = 2/15 L1, n = 13/15 L2, respectively). The proportion of surgical complications was very similar between INRGSS L1 and L2 (n = 4/11 vs. n = 17/34). All complications were manageable, and no surgery-related deaths were observed. In this retrospective cohort, the extent of resection and the rate of surgical complications did not differ substantially between patients classified as L1/L2, indicating that INRGSS L2 does not equate unresectability. It appeared that individual IDRFs differ in value. Larger studies are needed to assess the significance and therapeutic/prognostic impact of such findings.
Sections du résumé
BACKGROUND
The pretreatment International Neuroblastoma Risk Group Staging System (INRGSS) discriminates localized tumors L1/L2 depending on the absence/presence of image-defined risk factors (IDRFs) at diagnosis. Referring to this new staging system, we assessed initial imaging of localized thoracic neuroblastoma (NB) and ganglioneuroma (GN) and the extent of initial tumor resection.
METHODS
Patients with localized thoracic NB/GN from the German clinical trials NB97 and NB2004 were included. Imaging at diagnosis and operative reports were reviewed retrospectively. IDRFs were assessed centrally and correlated to International Neuroblastoma Staging System (INSS) stage and extent of tumor resection. Additionally, we analyzed data on surgery-related complications.
RESULTS
Imaging series of 88 patients were available for central review. In 18 children, no IDRF was present, 28 exhibited one IDRF, 42 two or more IDRFs, resulting in 70 patients with L2 disease. The most frequently observed IDRF was encasement of any vessel (n = 38). Initial surgical resection was aimed for in 45 patients (L1: n = 11; L2: n = 34). Complete and gross total resection rates were higher children with L2 NB (n = 8/25 L1, n = 17/25 L2 vs. n = 2/15 L1, n = 13/15 L2, respectively). The proportion of surgical complications was very similar between INRGSS L1 and L2 (n = 4/11 vs. n = 17/34). All complications were manageable, and no surgery-related deaths were observed.
CONCLUSION
In this retrospective cohort, the extent of resection and the rate of surgical complications did not differ substantially between patients classified as L1/L2, indicating that INRGSS L2 does not equate unresectability. It appeared that individual IDRFs differ in value. Larger studies are needed to assess the significance and therapeutic/prognostic impact of such findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30605Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008-3017. doi:10.1200/JCO.2014.59.4648
Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26(9):1504-1510. doi:10.1200/JCO.2007.12.3349
Smith V, Foster J. High-risk neuroblastoma treatment review. Children (Basel). 2018;5(9):114. doi:10.3390/children5090114
Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303. doi:10.1200/JCO.2008.16.6876
Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6(12):1874-1881. doi:10.1200/JCO.1988.6.12.1874
Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-1477. doi:10.1200/JCO.1993.11.8.1466
Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-297. doi:10.1200/JCO.2008.16.6785
Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group project. Radiology. 2011;261(1):243-257. doi:10.1148/radiol.11101352
Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73(2):405-416. doi:10.1093/jnci/73.2.405
Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2):364-372.
Simon T, Häberle B, Hero B, vonSchweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013;31(6):752-758. doi:10.1200/JCO.2012.45.9339
Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(9):649-658. doi:10.1016/S1470-2045(05)70291-6
Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs. 2017;19(6):577-593. doi:10.1007/s40272-017-0251-3
Simon T, Hero B, Schulte JH, et al. 2017 GPOH Empfehlungen für Diagnostik und Therapie von Patienten mit neuroblastischen Tumoren. Klin Padiatr. 2017;229(3):147-167. doi:10.1055/s-0043-103086
Simon T, Hero B, Benz-Bohm G, vonSchweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008;50(5):965-969. doi:10.1002/pbc.21343
Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26(12):791-796.
Kushner BH, LaQuaglia MP, Kramer K, Cheung N-KV. Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol. 2004;26(1):35-39. doi:10.1097/00043426-200401000-00012
Cecchetto G, Mosseri V, de BernardiB, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23(33):8483-8489. doi:10.1200/JCO.2005.02.4661
Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2014;32(28):3169-3176. doi:10.1200/JCO.2014.56.1621
Oldridge DA, Truong B, Russ D, et al. Differences in genomic profiles and outcomes between thoracic and adrenal neuroblastoma. J Natl Cancer Inst. 2019;111(11):1192-1201. doi:10.1093/jnci/djz027
Parhar D, Joharifard S, Lo AC, Schlosser M-P, Daodu OO. How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival in patients with neuroblastoma? A systematic review and meta-analysis. Pediatr Surg Int. 2020;36(8):897-907. doi:10.1007/s00383-020-04696-y
Zhang A-A, Pan C, Xu M, et al. Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma. World J Pediatr. 2019;15(6):572-579. doi:10.1007/s12519-019-00274-y
Avanzini S, Pio L, Erminio G, et al. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017;64(11):e26605. doi:10.1002/pbc.26605
Liu T, Lv Z, Xu W, Liu J, Sheng Q. Role of image-defined risk factors in predicting surgical complications of localized neuroblastoma. Pediatr Surg Int. 2020;36(10):1167-1172. doi:10.1007/s00383-020-04731-y
Yoneda A, Nishikawa M, Uehara S, et al. Can image-defined risk factors predict surgical complications in localized neuroblastoma? Eur J Pediatr Surg. 2016;26(1):117-122. doi:10.1055/s-0035-1566100
Boglino C, Martins AG, Ciprandi G, Sousinha M, Inserra A. Spinal cord vascular injuries following surgery of advanced thoracic neuroblastoma: an unusual catastrophic complication. Med Pediatr Oncol. 1999;32(5):349-352. doi:10.1002/(sici)1096-911x(199905)32:5<349:aid-mpo7>3.0.co;2-p
Schmidt A, Hempel J-M, Ellerkamp V, Warmann SW, Ernemann U, Fuchs J. The relevance of preoperative identification of the Adamkiewicz artery in posterior mediastinal pediatric tumors. Ann Surg Oncol. 2022;29(1):493-499. doi:10.1245/s10434-021-10381-8
Chou D, Narsinh K. Editorial. The relevance of the artery of Adamkiewicz in the 21st century. J Neurosurg Spine. 2022;38(2):230-231. doi:10.3171/2022.6.SPINE22532